Clinical trial Recruiting at 4 sites Observational Ages 7 and up

One-time DNA analysis for vasculitis

Official title: VCRC Genetic Repository One-Time DNA Protocol

Run by University of Pennsylvania · NCT01241305 · Data updated 2026-11-12

This study is testing whether analyzing DNA from people with different types of vasculitis can help find genetic factors that increase the risk of these diseases and lead to better treatments.

Quick facts

Study typeObservational
Ages7 Years and up
SexAll
Enrollment1000 (estimated)
SponsorUniversity of Pennsylvania
Academic / other
Locations14 sites (Los Angeles, California and 13 other locations)
StatusRecruiting
StartedOctober 2010
Main results expectedAugust 2028
Study endsAugust 2028
Registry record updatedJanuary 22, 2026
Trial IDNCT01241305 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Ideal candidates include individuals diagnosed with specific types of vasculitis, such as Giant Cell Arteritis or Takayasu's Arteritis.

Probably not a fit

Patients with vasculitis types not included in the study or those who do not meet the diagnostic criteria may not benefit.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study aims to identify genetic factors that increase the risk of developing various forms of vasculitis, which are severe inflammatory diseases affecting blood vessels. By collecting DNA samples from patients with specific types of vasculitis, researchers hope to gain insights into the underlying causes of these diseases. The findings could lead to new diagnostic tests and therapies, benefiting both vasculitis and broader autoimmune disease research. The study focuses on a range of vasculitis conditions, including Eosinophilic Granulomatosis With Polyangiitis and Giant Cell Arteritis.

Why it matters

Potential benefit: If successful, this study could enhance understanding of vasculitis and lead to improved diagnostic and therapeutic options for patients.

How similar studies have gone: Other studies have shown promise in genetic research related to vasculitis, but this approach aims to expand on previous findings with a larger cohort.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

1\. Diagnostic criteria for Giant Cell Arteritis Age at disease onset \>50 years (required)

1. New onset or new type of localized pain in the head
2. Temporal artery abnormality (i.e. temporal artery tenderness to palpation or decreased pulsation, unrelated to arteriosclerosis of cervical arteries)
3. ESR of \>40mm in the first hour by the Westergren method
4. Abnormal artery biopsy (i.e. temporal artery biopsy showing vasculitis characterized by a predominance of mononuclear cell infiltration or granulomatous inflammation, usually with multinucleated giant cells)
5. Large Vessel Vasculitis (LVV) by angiogram or biopsy not explained by something else

Inclusion Criteria:

2\. Diagnostic criteria for Takayasu's Arteritis

1. Age at disease onset \<50 years
2. Claudication of extremities
3. Decreased brachial artery pulse (one or both arteries)
4. Blood pressure difference of \>10mm Hg between the arms
5. Bruit over subclavian arteries or aorta
6. Arteriogram abnormalities compatible with TAK (includes conventional dye angiography or MR angiography or CT angiography)

Inclusion Criteria:

3\. Diagnostic criteria for Polyarteritis Nodosa Major criteria (not explained by other causes) felt by investigator to be due to vasculitis

1. Arteriographic abnormality
2. Presence of granulocyte or mixed leukocyte infiltrate in an arterial wall on biopsy
3. Mononeuropathy or polyneuropathy

Minor criteria (not explained by other causes) felt by investigator to be due to vasculitis

1. Weight loss \> 4 kg
2. Livedo reticularis, cutaneous ulcerations, or skin nodules
3. Testicular pain or tenderness
4. Myalgias
5. Diastolic blood pressure \> 90 mm Hg
6. Elevated BUN or serum creatinine levels
7. Ischemic abdominal pain

Isolated cutaneous Polyarteritis Nodosa 1. Biopsy-proven cutaneous PAN

Inclusion Criteria:

4\. Diagnostic criteria for Granulomatosis with Polyangiitis (Wegener's) (GPA) and Microscopic Polyangitis (MPA)

* Diagnosis of GPA or MPA. Widely accepted diagnostic criteria, as opposed to classification criteria or definitions, have not been developed for GPA \& MPA.
* For diagnosis of GPA meets at least 2 of the following 5 modified ACR criteria:

  1. Nasal or oral inflammation with oral ulcers or nasal discharge with pus or blood
  2. Abnormal chest radiograph with nodules, fixed infiltrates, or cavities
  3. Urinary sediment with microhematuria or red cell casts
  4. Granulomatous inflammation within the wall of an artery or in the perivascular area on biopsy
  5. Antineutrophil cytoplasmic antibody (ANCA) positive by enzyme immunoassay for either PR3- or MPO-ANCA
* For diagnosis of MPA, meets the Chapel Hill Consensus Conference Definition for MPA:

  1. Necrotizing vasculitis, with few or no immune deposits, that affects small vessels (i.e., capillaries, venules, arterioles)
  2. Necrotizing arteritis involving small- and medium-sized arteries may be present
  3. Necrotizing glomerulonephritis is very common
  4. Pulmonary capillaritis often occurs

     Inclusion Criteria:

     5\. Diagnostic criteria for Eosinophilic Granulomatosis with Polyangiitis (Churg-Strauss)
     1. Asthma
     2. Peak peripheral blood eosinophilia of \>10% of total WBC
     3. Peripheral neuropathy attributable to vasculitis
     4. Transient pulmonary infiltrates on chest imaging studies
     5. Paranasal sinus abnormalities or nasal polyposis
     6. Eosinophilic inflammation on tissue biopsy

     If patients have 4 of the above 6 criteria but lack clearcut documentation of small vessel vasculitis, they are also eligible for enrollment.

     General Exclusion Criteria:
* Inability to give informed consent and to sign the consent form
* Enrolled in VCRC protocols 5502, 5503, 5504, 5505, 5506, 5522, or 5523
* Unwilling to provide blood for DNA collection

Where it's running

  • Northwestern University
    Chicago, Illinois, United States
    Recruiting
  • University of Pennsylvania
    Philadelphia, Pennsylvania, United States
    Recruiting
  • St. Joseph's Healthcare
    Hamilton, Ontario, Canada
    Recruiting
  • Mount Sinai Hospital
    Toronto, Ontario, Canada
    Recruiting
  • Cedars-Sinai Medical Center
    Los Angeles, California, United States
    Completed
  • University of California, San Francisco
    San Francisco, California, United States
    Completed
Show 8 more locations
  • University of Kansas Medical Center
    Kansas City, Kansas, United States
    Completed
  • University of Michigan
    Ann Arbor, Michigan, United States
    Completed
  • Mayo Clinic
    Rochester, Minnesota, United States
    Completed
  • Hospital for Special Surgery
    New York, New York, United States
    Completed
  • Cleveland Clinic
    Cleveland, Ohio, United States
    Completed
  • University of Pittsburgh
    Pittsburgh, Pennsylvania, United States
    Completed
  • University of Utah
    Salt Lake City, Utah, United States
    Completed
  • Istanbul University
    Istanbul, Fatih, Turkey (Türkiye)
    Completed

Study contacts

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

  • Collection of tissue samples for vasculitis research

    This study is collecting tissue samples from patients with vasculitis to see if they can help researchers understand the disease better and find new ways to diagnose and treat it.

    Recruiting at 3 sites University of Pennsylvania · Boston, Massachusetts and 7 other locations · NCT02967068

  • Understanding the natural history and outcomes of systemic vasculitis

    This study is trying to understand how systemic vasculitis affects people over time and what signs can help predict how the disease will progress, involving both patients with vasculitis and healthy volunteers.

    Recruiting National Institutes of Health Clinical Center (CC) · Bethesda, Maryland · NCT02257866

  • Global Takayasu Arteritis Registry (GITA)

    The registry will collect past and ongoing medical information from people with Takayasu arteritis worldwide to see which treatments and patient features relate to better outcomes.

    Recruiting at 2 sites Marmara University · Istanbul, Istanbul and 1 other locations · NCT07558382

  • How optic nerve swelling changes after starting steroids in giant cell arteritis

    This study tests how quickly the optic nerve sheath swelling decreases after starting glucocorticoids in people with newly diagnosed giant cell arteritis.

    Recruiting Centre Integre Universitaire de Sante et Services Sociaux du Nord de l'ile de Montreal · Montreal, Quebec · NCT07508514

  • Butantan live tetravalent dengue vaccine for people with autoimmune rheumatic diseases

    This study will test whether a single dose of the Butantan live tetravalent dengue vaccine is safe and produces immune responses in clinically stable people aged 12–59 with autoimmune rheumatic diseases compared with matched healthy volunteers.

    Recruiting at 2 sites Phase 4 University of Sao Paulo General Hospital · São Paulo, São Paulo and 1 other locations · NCT07087912

  • Precision care for giant cell arteritis and polymyalgia rheumatica

    This long-term observational project will follow adults with giant cell arteritis or polymyalgia rheumatica to see if regular imaging, eye exams, blood tests, and immune cell profiling can better predict aortic complications and steroid side effects over 5–10 years.

    Recruiting Wuerzburg University Hospital · Würzburg · NCT07084480

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.